Managing medicines at the end of life: a position paper for health policy and practice by Latif, Asam et al.
Managing medicines at the end of
life: a position paper for health
policy and practice
Asam Latif
School of Health Sciences, University of Nottingham, Nottingham, UK
Christina Faull
LOROS Hospice Leicester, Leicester, UK
Justin Waring
Health Services Management Centre, University of Birmingham, Birmingham, UK
Eleanor Wilson
School of Health Sciences, University of Nottingham, Nottingham, UK
Claire Anderson
School of Pharmacy, University of Nottingham, Nottingham, UK
Anthony Avery
School of Medicine, University of Nottingham, Nottingham, UK, and
Kristian Pollock
School of Health Sciences, University of Nottingham, Nottingham, UK
Abstract
Purpose –The impact of population ageing is significant, multifaceted and characterised by frailty andmulti-
morbidity. The COVID-19 pandemic has accelerated care pathways and policies promoting self-management
and home-based care. One under-researched area is how patients and family caregiversmanage the complexity
of end-of-life therapeuticmedicine regimens. In this position paper the authors bring attention to the significant
strain that patients and family caregivers experience when navigating and negotiating this aspect of palliative
and end-of-life care.
Design/methodology/approach – Focussing on self-care and organisation of medicines in the United
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policy assumptions and unintended consequences for individual patients and family care givers as they
assume greater palliative and end-of-life roles and responsibilities.
Findings – Policy makers and healthcare professionals often lack awareness of the significant burden and
emotional work associated with managing and administering often potent high-risk medicines (i.e. opioids) in
the domiciliary setting. The recent “revolution” in professional roles associated with the COVID-19 pandemic,
including remote consultations and expanding community-based care, means there are opportunities for
commissioners to consider offering greater support. The prospect of enhancing the community pharmacist’s
medicine optimisation role to further support the wider multi-disciplinary team is considered.
Originality/value – The paper takes a person-focused perspective and adopts a holistic view of medicine
management. The authors argue for urgent review, reform and investment to enable and support terminally ill
patients and family caregivers to more effectively manage medicines in the domiciliary setting. There are clear
implications for pharmacists and these are discussed in the context of public awareness, inter-professional
collaboration, organisational drivers, funding and regulation and remote care delivery.
Keywords Palliative care, Community pharmacy, End-of-life
Paper type Viewpoint
Introduction
The commissioning and delivery of palliative care is inconsistent even in high-income
countries and it is estimated that only 14% of people judged to be in need currently receive it
(Etkind et al., 2017). For patients and family caregivers, the pressures of managing serious
illness including dementia and/or frailty are escalating and projected to rise significantly in
the coming decades (Sleeman et al., 2019). Effective deployment, use and administration of
medicines to deliver optimal relief of distressing symptoms is at the heart of effective
palliative care and critical for enabling dying patients to remain at home. For these patients,
end of life care depends on effective use of prescribed medication to manage common and
sometimes unpredictable symptoms including pain, nausea, delirium and breathlessness
(NICE, 2020).
The COVID-19 pandemic has had a substantial impact and advanced care delivery
pathways. The effort to enable social distancing and reduce pressure on the NHS has led to
increases in remote and e-Health technologies. The longer-term impact of these changes on
the delivery of care to older people and to vulnerable groups is unknown. However, they have
inadvertently quickened the gradual shift towards policies promoting patient self-
management of chronic and terminal diseases (Lederle and Bitzer, 2019). Consequently,
expectations to self-manage care have become more prevalent. Family caregivers are also
being encouraged to adopt work analogous to the complex tasks traditionally performed by
health professionals including assessments, monitoring and judging when and how to act to
manage symptoms and side effects (Antunes et al., 2020).
As well as drug administration, the associated work of medicines management is often
underestimated and has recently become more complicated. New care pathways and remote
prescribing practices contribute to this complexity. As co-morbidities and the number of
medicines used by older people continue to increase, there will be a greater emphasis on
resolving issues including non-adherence, adverse effects and problematic polypharmacy.
The question arises as to how the healthcare system can support self-management and, more
specifically, whomay be best placed to offer this help. In this position paper we identify some
of the unintended consequences of palliative and end-of-life medicine management in the
domiciliary setting. Our principal aim is to give voice to patients and family caregivers,
expose the burdens placed on them when managing complex medicines regimes. Finally, we
offer insight into the potential for community pharmacy to assume a greater professional role.
The shifting care landscape: consequences for patients and families
Before the onset of the pandemic, policy approaches encouraging the public to become more




agendas promoting autonomy and choice (Vadiee, 2012). Commitments to enable patients to
die at home are largely seen to be in step with expectations that this is the preferred place and
choice of the majority (Gomes et al., 2011). It is assumed that patients and their family
caregivers would be willing to engage in self-management to enable better forward planning
and the eventual “good death”. Shifting the place of death from hospital to home is also an
arrangement that is economically less costly (McCaffrey et al., 2015). In the UK, the NHS long
term plan advocates out-of-hospital care by promoting a contemporarymodel of self-care and
management to support proactive, personalised and well-coordinated care for all people in
their final year of life (NHS England, 2019).
However, concerns have been raised that the home is increasingly becoming encroached
upon, becoming “annexed” as an extension of the hospital. The promotion of norms about
managing end-of-life care at home without adequate examination of the unintended adverse
consequences could result in constraining rather than enabling patient “choice” (Pollock,
2015; Milligan et al., 2016). While some level of self-management may be desirable during the
course of an illness, end-of-life care poses different and complex challenges that often require
professional support. Patients will often become too ill to manage care themselves and family
caregivers may also have their own frailties and comorbidities. Mair and May (2014) aptly
reframe the context from asking how over-stretched healthcare systems can cope with rising
demands from patients to asking how overburdened patients and family caregivers are able
to cope with the unrelenting demands imposed on them by an overly complex, fragmented
and bureaucratic system.
The pandemic has further impacted on how palliative and end-of-life care is managed.
Social isolation, fear of contracting COVID-19 and caution not to overburden the NHS have all
determined the way care is perceived, accessed and delivered. There is also increased
pressure on family caregivers to assume greater responsibility for decisions about
administering medicines in cases where healthcare professionals may be absent (NICE,
2020). If policies promoting self-management at home are not carefully governed, the delivery
of care can quickly become burdensome for both patients and especially family caregivers.
The escalation of eHealth services has also quickened, offering efficient, convenient and safe
means for patients to access health and medicines advice. For example, the adoption of
telemedicine to remotely monitor health and support self-care is now largely seen as a means
to avoid cross-contamination between patients and front-line health workers; consequently
telemedicine is becoming a widespread alternative to face-to-face consultations (Bokolo,
2021). The drawback of these new advancements may risk excluding people from minority
groups, those who are not “user ready” or who may be digitally disadvantaged in other ways
(Sutherland et al., 2020).
There remains an underestimation of the support needed for patients and family
caregivers to effectively self-manage care and COVID-19 has added to this burden. The
managing medicines study (Pollock et al., 2021) reinforced earlier findings that it is often the
day-to-day practical problems associated with medicine use that lead to unintentional non-
adherence. Concerns and anxiety can also arise around poor symptom control and
administering potent medicines (e.g. opioid controlled drugs) (Wilson et al., 2018). The study
also raises questions about what can reasonably be expected of patients and family
caregivers in managing palliative and end-of-life care medicines and highlights the need for
greater professional understanding and support (Box 1). System-wide review, reform and
investment is needed to protect those who are most vulnerable. They are least likely to resist
self-management discourses or possess the social or economic capital required for self-
management of complex treatment regimens at home. However, reducing this burden of care
will require far reaching changes to service organisation and delivery andmay also impact on
(inter) professional roles and boundaries. One option could be to consider contracting




and who could assume greater roles in palliative medicine management services (O’Connor
et al., 2011; Latif et al., 2020).
A case for greater community pharmacist involvement
In England, public access to the 11,500 community pharmacies is good with approximately
90% being located within a twenty-minute walk of where people live (Todd et al., 2014).
Pharmacists provide a range of professional services including medication reviews (Latif
et al., 2017), advise on healthy living (Nazar et al., 2019) and services that promote self-care
(Anderson and Sharma, 2020). During the pandemic, pharmacies saw a rise in the numbers of
people accessing their services as the public struggled or were reluctant to access other
healthcare providers such as GPs and hospitals. In this time, pharmacists’ have shown
innovation, adaptability and flexibility to assume new roles. This has included
accommodating COVID-19 vaccinations, which has been particularly evident in response
to the unique challenges that the pandemic lockdown posed (Cadogan and Hughes, 2021). In
addition, the pandemic has exposed deeper inequalities with marginalised groups being
disproportionally affected by COVID-19 (Bambra et al., 2020). Others have highlighted that
pharmacy provision follows a “positive care law” where a greater number of pharmacies are
Box 1. Overview of findings from the “Managing medicines for patients with
serious illness being cared for at home” study.
This qualitative investigation explored how patients, their family caregivers and
health care professionals engage in the tasks of managing complex medication
regimens for patients with severe and terminal illness.
(1) Patients and families often engaged in demanding and complex “work” in managing
medications at the end of life. This work involved practical, physical and emotional
components. It was organised in terms of space and place and embeddedwithin the goals
and activities involved in carrying on with normal life. Others have also highlighted the
problem of delayed access to medicines via community pharmacies due to unavailability
of stock and lack of coordinated communication between the pharmacy, health
professionals and patients (Ogi et al., 2021).
(2) There was often little professional engagement, guidance or information on how to
manage the practical aspects of medicines management or understanding of the
problems and concerns that these could pose.
(3) As the patient’s health deteriorated family caregivers increasingly assumed the role of
care coordinator, managing all aspects of medicinesmanagement. Participants described
the need tomaintain vigilance about themedicines prescribed for their relative, especially
when changes were made by different professionals who lacked knowledge of the case.
Managing complex medicines in the home added to an already substantial workload of
organising other aspects of palliative care and so further depleted patient and family
caregivers’ physical and emotional resources.
(4) Palliative, health and social care arrangements were experienced as complex and often
fragmented or poorly coordinated. This was particularly problematic during the later
stages of the patient’s illness, when deterioration could be rapid with frequent changes to
symptom burden and prescribed medication.
(5) Establishing a relationship with a key professional who could help families negotiate the
health care system had a significant positive impact on experience of care.
(6) Patients and family caregivers were often unaware of the help and support the
pharmacist was able to provide. It was clear the potential for pharmacists to help patients




found in areas of highest deprivation (Todd et al., 2014). The greater access in such areas
means there is potential for pharmacist to play a valuable part in promoting and delivering a
more equitable service.
In addition to their existing roles, pharmacists could further contribute to enhancing
palliative care services by building system capacity and resilience (i.e. Safety-2 harm
reduction approaches) (Hollnagel et al., 2015). This could be realised through coordinating
and advising onmedicine optimisation and administration (including anticipatorymedicines)
and brokering the gaps between professions aroundmedicine prescribing, deprescribing and
use (Wilson et al., 2020). For example, palliative domiciliary medication reviews could be
made available for those unable to travel to the pharmacy or via “telemedicine” to those
hesitant or unable to attend in person (Calton et al., 2020). There are already promising
pharmacist-led palliative care support services emerging. Good examples of these include the
Rural Palliative Care Pharmacist Practitioner project (Akram et al., 2017) and medicines
optimisation services for patients with advanced cancer pain (Edwards et al., 2019) (Table 1).
Benefits may also be seen with initiatives that seek to upskill community pharmacy support
staff as observed in the evaluation of the “MacMillan pharmacy service” (Bennie et al., 2015).
For patients and family caregivers, an assigned pharmacist as a single point of contact
may hold significant benefits. Thismay include dedicated support for patients and families in
managing complex medicines regimes and help in navigating a complex and sometimes
bureaucratic system of care. A striking finding from the managing medicines study was the
notable lack of patient, family caregiver and professional awareness and use of the
community pharmacist’s knowledge, skill sets and ability to provide advice and support for
medicine-related issues or problems (Pollock et al., 2021). Even established NHS funded
medication review services that aim to improve patients’ knowledge of medicines and use
(Latif et al., 2017) did not feature as strongly as one may have hoped. Therefore, alongside
service development and reconfiguration, comprehensive public awareness strategies and
campaigns are needed to showcase pharmacist roles and responsibilities to foster “help-
seeking” behaviours. The initial aim should be for all patients and family caregivers to be able
to be aware of and be able to easily access expert help and advice on medicines management
and symptom control whenever they feel this is necessary.
Community pharmacy service Brief details of the intervention
MacMillan Rural Palliative Care Pharmacist
Practitioner (MRPP) project (Akram et al., 2017)
• Better professional integration of the MRPP in
different care settings and teams and promote
awareness of the clinical skill set of pharmacists
• Development of medicine related educational
resources for other health and social care professionals
• Point of contact for advice on sourcing medicines
•Bespoke training on pharmaceutical matters for care
home staff
Community pharmacist medicines optimisation
service for patients with advanced cancer pain
(Edwards et al., 2019)
• Delivery of one patient-pharmacist face-to-face or
two telephone “medicines optimisation”
consultation(s) (∼20–30 min)
• Format of the consultation was based on the
community pharmacy Medicine Use Review (MUR)/
New Medicine Service (NMS)
• Advice to manage medicine-related problems










Overcoming barriers: realising the vision
Public awareness
As mentioned, by and large, public awareness of the potential for community pharmacy
services to provide medicine support, beyond supplying dispensed medicines and managing
minor ailments, remains low (Hindi et al., 2018). Nevertheless, there is evidence that
pharmacists are able to significantly help patients minimise harm from high-risk medicines.
Examples include reducing the opioid load, improving symptom management, promoting
risk-mitigation strategies and reducing adverse clinical outcomes (Jordan et al., 2021).
Concerted efforts are needed to raise patient, caregiver and professional awareness and
expectations to promote pharmacists’ skills in managing more than simple minor ailments
(Mossialos et al., 2015; Tait et al., 2013). However, care is needed not to overpromise and under
deliver. Future research should therefore explore the variability in pharmacy’s preparedness
andwillingness to deliver such professional support, their capacity to implement services and
how this may be constrained by factors such as existing workload, organisational and
contractual barriers.
Inter-professional collaboration
With a growing number of pharmacists in the UK becoming independent prescribers,
pharmacists are well placed to improve safety, manage medicines and alleviating GP
workforce pressures (Stone and Williams, 2015). Reconfiguring care to enable an increased
contribution of pharmacists will require collaboration including discussions around a more
comprehensive shared access of medical records between different professional groups.
Despite the good progress made in integrating GP-practice based pharmacists within the
wider multi-disciplinary team, barriers for the community pharmacist remain and include
factors such as the historical power imbalance in GP-pharmacist relations, differing
contractual goals and pharmacists working remotely in relative silos (Waring and Latif,
2018). Factors that have been shown to encourage interprofessional collaboration include
early-career co-education to foster understanding of each other’s skills and knowledge and
utilising compatible technologies to facilitate communication between professional groups
(Bollen et al., 2019). Again, further research is needed and should seek to explore how such
measures could impact on GPs and pharmacist collaboration, how they may organise work
and how patients can be a full partner in any such arrangement.
Organisational drivers, funding and regulation
Joint contractual arrangements and “quality-driven incentives” have been proposed to
promote pharmacist integration within the patient’s primary care pathway (Hindi et al., 2019).
“Primary Care Networks” (PCNs) offer an opportunity for policy makers and commissioners
to acknowledge, integrate and extend community pharmacist’s roles to fully optimise
medicine support to patients and caregivers. These networks are assuming contractual
responsibilities and promoting integrated care. The NHS, local authorities, voluntary and
community organisations will be working together to take responsibility for the resources
and health of a population in a defined area (Anderson and Sharma, 2020). With appropriate
funding, strategic vision and motivation, substantial change is possible. Furthermore, NHS
leaders in England are pursuing changes to the healthcare system, structures and legislation
via new “integrated care systems” (ICSs) (NHS England and NHS Improvement, 2020). While
the proposals do offer hope for a better coordinated service between health and care
organisations, concerns have been expressed as to whether the timing of these proposals will
help or hinder the recovery from the pandemic (Alderwick et al., 2021). Further investigation
is needed to evaluate the implications of reorganisation, how the proposed changes will work





Another opportunity that emerged during the pandemic was the ways information
technology was better deployed to engage with and gather patient data outside traditional
healthcare settings. Going forward, a full assessment is needed to fully take advantage of
these remote eHealth strategies. Reconfiguration of existing care models may be needed
including implementation and training for professionals and policy ambitions to use this
technology proactively rather than reactively to achieve sustained benefits in the long-term
(Smith et al., 2020). Social, technological and organisational factors should be considered to
overcome barriers to accessing support and through this reduce the burden of self-care at a
distance (Bokolo, 2021). Pockets of progress can be seen in Wales where funding streams for
specialist palliative care services have become more evident resulting in service innovations.
Practically this includes 24-h access to a specialist consultant offering telephone advice,
pharmacy services to improve access to medicines and funding to support professional
education (Welsh Government, 2013). Future research in this area should seek to assess
public and professional acceptance of eHealth, implementation, effectiveness and cost-
effectiveness of community pharmacist-led palliative medicine management models.
Conclusion
Before the pandemic, commentators suggested the delivery of care to the elderly was already
at a crisis point and heading towards the “brink of disaster” (Dann, 2014). The COVID-19
pandemic has posed new challenges but has also led to innovations in the way healthcare is
organised and managed. With an ageing population, there will continue to be growing
demands for palliative and end-of-life care with mounting pressures on primary, secondary
and acute care services. A “left shift” in expectations (moving care downstream into the
community) will inevitably lead to patients and their families assuming greater responsibility
for self-care. Effectivemedicinesmanagementwill always be the cornerstone to enable care to
be optimised for serious illness and at the end-of-life. It is currently unknown how the legacy
of the pandemic will impact on the long-term organisation and delivery of care. We
acknowledge that this is a limitation of our understanding. What should be central to any
further research and debate is a greater understanding of the extent to which patients and
family caregivers are willing or even able to self-manage complex medicine regimens and
how professionals can best support them.
In the UK, and elsewhere, community pharmacy services are expanding and the paper
suggests clear implications for pharmacists. Considering the additional challenges the
pandemic has brought, we call for urgent review, reform and investment to support greater
involvement of pharmacists in medicine management for patients approaching the end-of-
life. This underlines the considerable scope and potential for contracting pharmacists as part
of the multi-disciplinary team to support medicine optimisation and counselling that could
help patients and family caregivers (Nadeem et al., 2021). With appropriate remuneration,
organisational support and public awareness campaigns, the community pharmacist is well
positioned to provide much needed support for pharmaceutical care to patients approaching
the end of life.
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